KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Aquestive Therapeutics (AQST) Leases (2019 - 2026)

Aquestive Therapeutics has reported Leases over the past 7 years, most recently at $4.6 million for Q4 2025.

  • For Q4 2025, Leases fell 10.83% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, down 10.83%, while the annual FY2025 figure was $4.6 million, 10.83% down from the prior year.
  • Leases for Q4 2025 was $4.6 million at Aquestive Therapeutics, down from $4.8 million in the prior quarter.
  • Over five years, Leases peaked at $5.9 million in Q1 2023 and troughed at $2.1 million in Q3 2022.
  • A 5-year average of $4.4 million and a median of $5.0 million in 2025 define the central range for Leases.
  • Biggest five-year swings in Leases: fell 28.21% in 2022 and later soared 170.73% in 2023.
  • Year by year, Leases stood at $2.7 million in 2021, then soared by 91.23% to $5.2 million in 2022, then rose by 6.64% to $5.6 million in 2023, then decreased by 6.75% to $5.2 million in 2024, then fell by 10.83% to $4.6 million in 2025.
  • Business Quant data shows Leases for AQST at $4.6 million in Q4 2025, $4.8 million in Q3 2025, and $4.9 million in Q2 2025.